GH Research (GHRS) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.23

Estimate

-$0.33

Surprise

+30.3%

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

GH Research (GHRS) reported a narrower loss than forecast — diluted EPS of -$0.23 against the -$0.33 estimate (a 30.3% beat on a still-unprofitable quarter).

TrendMatrix currently rates GHRS Sell at 5.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +30.3% surprise compares with a +7.7% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$27.85

Price target

$37.31

Stop

$25.81

Upside to target

+34.0%

Reward-to-risk

4.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.89B

P/E (fwd)

-14.9

52-week range

$12.04–$31.44

Off 52-week high

11.4%

RSI (14)

39

Volume vs avg

0.87×

Score today

5.6/10